MoonLake Immunotherapeutics cotiza a 10.41 USD y tiene una capitalización bursátil de $886M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hi…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.84 | $-0.98 | $-0.92 |
| Estimado | $-0.78 | $-0.90 | $-0.92 | $-0.94 |
| Sorpresa | — | +6.7% | -6.5% | +2.1% |
| Métrica | MLTX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -74.7% | -40.4% | -34.3% |
| ROA | -53.6% | -32.0% | -21.6% |
| Current Ratio | 9.27 | 2.84 | +6.43 |
| Debt / Equity | 0.24 | 0.28 | -0.04 |